Nucleome will use its proprietary machine learning and high-resolution 3D genomics technologies to unambiguously define the specific DNA changes that make patients more susceptible to certain autoimmune diseases and identify the pathological mechanisms underlying those diseases.
Using Nucleome’s technology, and in combination with Johnson & Johnson’s immunology and data sciences capabilities, the collaboration aims to discover new target genes and the cell types that drive autoimmune disease. Ultimately this information could facilitate the classification of patients most likely to respond to therapy.
Dr Stephen Harrison, CSO of the Nucleome, said:
We are delighted to be working with J&J to identify new targets and develop strategies for patient stratification in autoimmune disease. Nucleome’s unique technology will be used to identify how genetic differences affect gene function and how this drives disease, specifically by defining the relevant genes and cell types.
*Facilitated by Johnson & Johnson Innovation